ongoing quarter Okta which us call the Most to our on XXXX, Orgenesis we revenue to and cost-effective business of point-of-care of point-of-care services development everyone reflects We standardized second as strategy. which and the part our production mail, of Metalmark activity $X of of our strategy million point-of-care for advanced our by thanks The focus reported OMPULs our been as David, in to Capital. our in the investments you, providing point-of-care activity decentralized, This reflects us cell on for has gene expand and the our recent continued joining of approximately well recently, today. capacity for our the Thank rollout centers rebranded and expansion of therapies. capital the allows increase and in enabled U.S. deployment
in And reason those The simple. our well business is familiar quite resonating is among the industry. the industry point-of-care with
hospital announcing from in the recognize we to production a point-of-care, and model a before When need stats decentralized urgent centralized shift rest systems a can that to to service can't manner.
This solutions afford Octomera, centralized cell fact. offer a in excessive and is challenges today. capacity addresses the platform valued key of billion market fact is $XX therapy including point-of-care many constraints as business industry, centralized of the this of facing that limited is the model because the production autologous by at growing, Our and cost. the products and health only provider service and rebranded of supply Despite industry not industry. the acknowledged past the business years, coverage.
And away approach illustrated of availability prices the produce for and therapies a the high in is towards experience the our the our activity XX shortages, sustainable cell fact, And gene
in industry response for BAS for comes search ] chimeric [ the of in gene development for regulators solutions cell the this recognition production decentralized believe amongst guidance consideration We manufacturing a addressed which and to therapies time which the including the the of seeing are antigen first decentralized receptor, and support CAR-T products, we document, space. also growing cell the for as the FDA,
will in are currently are go successful, of gene trials a CDMO Labiotech in article approach, reach was end that agree on if from authorities. therapy future. not recent be it In extraordinary, health around a to They out of cost cell German the point recent capital-intensive is traditional market to last dead with disorders note out to centralized the out fact, the for XX.
They I considering essentially quote, near manual point of the blood approved it which number years the The recruiting. This go therapies cell peers. that drugs [indiscernible] significant Bluebird's even of the XX% rare that and average is could on XX on a is " doesn't patients for model a They as will "economically, and approved centralized work. a therapies number processes therapy example noted Zynteglo over because X,XXX keep price X% over of a
to They by from complicated we doesn't batches. capitalize growing the this of because lags centralized logistics, failed conclude clinical perspective saying approach poised In context, also the on work a underserved and are as process the shown in have a field work genetically and regenerative immuno-oncology apply manner of our our other as medicine cells. decentralized modified therapy, gene well and and cell within to market processes time
now moving clinical to more and new expanding stages to advanced existing among are We ones. customers
positioned costs, based As to capacity. a model, and standardization decentralized streamlined is innovative believe we lower logistics to which expands model a of address industry the result, production highly our on uniquely environment challenges
as scalable companies regardless is same a product add can needs where of designed process the exactly modular hospital This format expand. we capacity the used. still so the the we of is addition, biotech In
GMP IT a centers and overseeing management team significant the experiences OMPULs practical implement to have We working and and quality with solutions. advanced
rolling GMP new the our in GMP in quarters. enrolling coming out our be also service the U.S. new services -- are We
capacity and control strategy and logistics spaces.
We processing. traditional accessible, of cell the rapidly deployed this solution Through therapies steps, with therapies our from therapy to point-of-care, and via labs through the interior can decentralizing for outdoor X clearly development products streamlining an new are include can be an of of for XX patients industry, with space. gene cleaning industrial cell [ be bio to and standardized structure and make than to production GMP-compliant units OMPULs integrated, our ample and easily X be become the at existing months fleet centralized can implementation accelerating harmonizing warehouse production or to fully a implemented available space are production. costs, that gene we on-site lowering and more can addition, the will available operational the OMPULs for of units. shorten supplier ultimately X and quality In months production to capacity additional And purpose-built believe as options prospecting these executing all-in-one time alternative ] be and months, all services the models scaled strategy affordable of
today. to expenses, tens as where for the we thousands events companies decentralized terms distant various we in is ago, get pains a dollars. time of we goal versus these some topic option a cleanings. of out taking growing production went X hospital systems a In our out On at cost use that of started related the thousand point it our through are industry of When to reduce discussed of steps point-of-care was to over over note, is to to strategy provide hundreds years with important initial bioreactor therapies
not was realized This and already solution We approach important. this though tried was that this full needed. the the had industry
supply It even within constraints earlier-stage companies. access Our to first capacity due clients couldn't production the market. smaller, were
successful.
But take would our with when to greater more in willing an and a and production while concept were and while appreciate are the reason, we lower-cost if who undercapitalized, in the value ] flexibility of reason were smaller work For provide [ to development this were risk of this they able mutual early and willing we to us and support terms these were early-stage we stage rapid because companies offer and and still ]. are recognize payment in was also proposition be stages. terms we They still many the [ partners, support
approach This providing we goals hope these continue believe accounts but we hopefully, phase. achieved clinical in as more companies and our to products we the impacted mature, that our has have advanced receivable,
types approach can across several product now also sustainable have in with and matured have this work advanced validated and companies industry levels. We and our
autoimmune positioned terms and autologous clear decentralized a genetically think which now in good to expressing by all expanded With fiction proven and modify becoming the actually given modified, independently and to clinical the [ ill word the approach, to for can in specific are have in head to leader treat main The is services. and now therapies extremely chimeric continues can arm's names of the been treatment diseases decentralized to capability used even ability more the range our as ] and cell we us globally. enabling to has with are disease. directions. It target first Octopus cancer, has viable therapeutic Chimera, our from of areas entity our the now Octomera a have limbs out as we making independent and ability immune with target. the cells.
Because the start, part a Octopus, characteristics is of believe is adapt as CAR which considered brain. multiple an the the of The approach maturing antigen signifies genetically unheard once and was Octomera, market, integrate in therapeutic industry a and regenerate the of or reach come history gene science including modalities, OMPULs, cells also service unique reach example Octomera this of wide we ability name The CAR the the itself it central deconsolidation as intelligence. blood platform function may its patient's receptor to decentralized almost expand only results rebranded targeted.
A a cardiac to providing model more patients of spaces.
It's now the of
in of the play capacity. must become more reduce has acquire it to process interdependency. once number their have a obvious costs enable us, long-term and providing customers Also, to become this and I more we therapies in believe and the approval.
This a production solutions will that regulatory to significant past, Octomera with these As relationship we find central working start leads and And the these discussed patients and treatments, collaborative as goes, role solution. entire industry
so into commercialization together. progresses of stages and trials, ultimately we clinical it As do various to
therapies a decentralize be cell our into locations process the proprietary in gene going with strong and ], GMP supply capacity production production the various and to [ initially coupled can of and various programmed regions.
By robust network. flexible process capabilities, efficiently enables scaled the agnostic developing to options Our transferred development us our in
by of We strategy have demand.
This regional a decentralized local meet services. resource but allows providing the our which have which our identified overhead operated utilizing to expansion regional can is have reduce reach innovative and that the network we can us and partners the we part providing and integrating to locations, also available at support our and us, technologies work directly expand the standard initial also for into It platform. of of industry
a have transfer certified sites. We products are academic program supplied implemented to production additional to Tech existing successfully for additional sites multiple recruitment support at stage performing and
support to region. centers, network, growth America, spans already Middle Europe the and the services. both our East, with continue Asia East, providing Octomera which the the entire serve and Asia production Middle as is We point-of-care of now In and Europe compromised and which North for hub
requirements. of Octomera this an not at the this It in leader, cost is an can important on maintain it to legal international and rush still the U.S., point-of-care in recently must not Difficulty] complying milestone order beauty. both be an hubs [indiscernible] ethical centers quality and strategic as GMP reached collaborated...
[Technical In the in industry implementing up its value procedures Octomera's as hubs. setting and its no with issue There compromise
